Literature DB >> 12361741

Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca.

Mercedes Yritia1, Jordi Riba, Jordi Ortuño, Ariel Ramirez, Araceli Castillo, Yolanda Alfaro, Rafael de la Torre, Manel J Barbanoj.   

Abstract

Ayahuasca is a South American psychotropic beverage prepared from plants native to the Amazon River Basin. It combines the hallucinogenic agent and 5-HT(2A/2C) agonist N,N-dimethyltryptamine (DMT) with beta-carboline alkaloids showing monoamine oxidase-inhibiting properties. In the present paper, an analytical methodology for the plasma quantification of the four main alkaloids present in ayahuasca plus two major metabolites is described. DMT was extracted by liquid-liquid extraction with n-pentane and quantified by gas chromatography with nitrogen-phosphorus detection. Recovery was 74%, and precision and accuracy were better than 9.9%. The limit of quantification (LOQ) was 1.6 ng/ml. Harmine, harmaline, and tetrahydroharmine (THH), the three main beta-carbolines present in ayahuasca, and harmol and harmalol (O-demethylation metabolites of harmine and harmaline, respectively) were measured in plasma by means of high-performance liquid chromatography (HPLC) with fluorescence detection. Sample preparation was accomplished by solid-phase extraction, which facilitated the automation of the process. All five beta-carbolines were measured using a single detector by switching wavelengths. Separation of harmol and harmalol required only slight changes in the chromatographic conditions. Method validation demonstrated good recoveries, above 87%, and accuracy and precision better than 13.4%. The LOQ was 0.5 ng/ml for harmine, 0.3 ng/ml for harmaline, 1.0 ng/ml for THH, and 0.3 ng/ml for harmol and harmalol. Good linearity was observed in the concentration ranges evaluated for DMT (2.5-50 ng/ml) and the beta-carbolines (0.3-100 ng/ml). The gas chromatography and HPLC methods described allowed adequate characterization of the pharmacokinetics of the four main alkaloids present in ayahuasca, and also of two major beta-carboline metabolites not previously described in the literature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361741     DOI: 10.1016/s1570-0232(02)00397-5

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Pharmacology of ayahuasca administered in two repeated doses.

Authors:  Rafael G Dos Santos; Eva Grasa; Marta Valle; Maria Rosa Ballester; José Carlos Bouso; Josep F Nomdedéu; Rosa Homs; Manel J Barbanoj; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2011-08-13       Impact factor: 4.530

Review 2.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

3.  Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.

Authors:  Nicholas V Cozzi; Anupama Gopalakrishnan; Lyndsey L Anderson; Joel T Feih; Alexander T Shulgin; Paul F Daley; Arnold E Ruoho
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

4.  Serotonergic psychedelics temporarily modify information transfer in humans.

Authors:  Joan Francesc Alonso; Sergio Romero; Miquel Àngel Mañanas; Jordi Riba
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-28       Impact factor: 5.176

5.  An ontogenic study of the behavioral effects of chronic intermittent exposure to ayahuasca in mice.

Authors:  N F Correa-Netto; M Y Masukawa; F Nishide; G S Galfano; F Tamura; M K Shimizo; M P Marcato; J G Santos; A Linardi
Journal:  Braz J Med Biol Res       Date:  2017-06-05       Impact factor: 2.590

Review 6.  N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function.

Authors:  Steven A Barker
Journal:  Front Neurosci       Date:  2018-08-06       Impact factor: 4.677

7.  The pharmacological interaction of compounds in ayahuasca: a systematic review.

Authors:  Simon Ruffell; Nige Netzband; Catherine Bird; Allan H Young; Mario F Juruena
Journal:  Braz J Psychiatry       Date:  2020 Nov-Dec       Impact factor: 2.697

8.  Ayahuasca and cancer treatment.

Authors:  Eduardo E Schenberg
Journal:  SAGE Open Med       Date:  2013-10-18

9.  Harmine stimulates proliferation of human neural progenitors.

Authors:  Vanja Dakic; Renata de Moraes Maciel; Hannah Drummond; Juliana M Nascimento; Pablo Trindade; Stevens K Rehen
Journal:  PeerJ       Date:  2016-12-06       Impact factor: 2.984

Review 10.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.